BRPI0719481A2 - " composto, método de indução de apoptose em uma célula, de sensibilização de uma célula, para inibir a ligação de uma proteína iap a uma proteína caspase, para tratar uma doença ou condição associada com a superexpressão de uma proteína iap e para tratar câncer" - Google Patents

" composto, método de indução de apoptose em uma célula, de sensibilização de uma célula, para inibir a ligação de uma proteína iap a uma proteína caspase, para tratar uma doença ou condição associada com a superexpressão de uma proteína iap e para tratar câncer" Download PDF

Info

Publication number
BRPI0719481A2
BRPI0719481A2 BRPI0719481-1A BRPI0719481A BRPI0719481A2 BR PI0719481 A2 BRPI0719481 A2 BR PI0719481A2 BR PI0719481 A BRPI0719481 A BR PI0719481A BR PI0719481 A2 BRPI0719481 A2 BR PI0719481A2
Authority
BR
Brazil
Prior art keywords
alkyl
heterocycle
optionally substituted
carbocycle
amino
Prior art date
Application number
BRPI0719481-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael F T Koehler
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0719481A2 publication Critical patent/BRPI0719481A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0719481-1A 2006-12-19 2007-12-14 " composto, método de indução de apoptose em uma célula, de sensibilização de uma célula, para inibir a ligação de uma proteína iap a uma proteína caspase, para tratar uma doença ou condição associada com a superexpressão de uma proteína iap e para tratar câncer" BRPI0719481A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87082106P 2006-12-19 2006-12-19
US60/870,821 2006-12-19
PCT/US2007/087532 WO2008079735A1 (en) 2006-12-19 2007-12-14 Imidazopyridine inhibitors of iap

Publications (1)

Publication Number Publication Date
BRPI0719481A2 true BRPI0719481A2 (pt) 2014-02-11

Family

ID=39361343

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719481-1A BRPI0719481A2 (pt) 2006-12-19 2007-12-14 " composto, método de indução de apoptose em uma célula, de sensibilização de uma célula, para inibir a ligação de uma proteína iap a uma proteína caspase, para tratar uma doença ou condição associada com a superexpressão de uma proteína iap e para tratar câncer"

Country Status (12)

Country Link
US (2) US8063218B2 (enExample)
EP (1) EP2125809A1 (enExample)
JP (1) JP2010513561A (enExample)
KR (1) KR20090094461A (enExample)
CN (1) CN101605786A (enExample)
AU (1) AU2007337104A1 (enExample)
BR (1) BRPI0719481A2 (enExample)
CA (1) CA2671607A1 (enExample)
IL (1) IL198927A0 (enExample)
NZ (1) NZ577150A (enExample)
RU (1) RU2466131C2 (enExample)
WO (1) WO2008079735A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773766B1 (en) * 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP2009512719A (ja) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Iapbirドメイン結合化合物
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
AR063943A1 (es) * 2006-07-24 2009-03-04 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CN101687787A (zh) * 2007-04-30 2010-03-31 健泰科生物技术公司 Iap的抑制剂
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
KR20100110870A (ko) * 2008-01-11 2010-10-13 제넨테크, 인크. Iap의 억제제
NZ590550A (en) * 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer
US20110218211A1 (en) * 2008-08-16 2011-09-08 Genentech, Inc. Azaindole inhibitors of iap
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
PL2611797T3 (pl) * 2010-08-31 2017-05-31 Hanmi Science Co., Ltd. Pochodne chinoliny lub chinazoliny o aktywności wywoływania apoptozy wobec komórek
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
WO2019091492A1 (zh) * 2017-11-13 2019-05-16 南京明德新药研发股份有限公司 用作iap抑制剂的smac模拟物及其用途
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
AU2020233068B2 (en) * 2019-03-07 2025-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination of IAP inhibitor and immune checkpoint inhibitor
EP3967702B1 (en) * 2019-05-10 2024-03-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystallization of smac mimic used as iap inhibitor and preparation method thereof
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3685626T2 (de) 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
US4935494A (en) 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5559209A (en) 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
EP1315811A2 (en) 2000-08-24 2003-06-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
AU2002253908A1 (en) 2001-02-08 2003-02-17 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
MXPA03010762A (es) 2001-05-31 2005-03-07 Univ Princeton Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap.
US20030157522A1 (en) 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
CA2491041A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ES2318167T3 (es) 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
AU2003216203A1 (en) 2003-02-07 2004-09-06 Genentech, Inc. Compositions and methods for enhancing apoptosis
US20040171554A1 (en) 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
SE0301904D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US7067274B2 (en) 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
CA2582734C (en) 2004-03-01 2011-05-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
EP2253614B1 (en) * 2004-04-07 2012-09-19 Novartis AG Inhibitors of IAP
MXPA06014969A (es) 2004-07-02 2007-02-08 Genentech Inc Inhibidores de iap.
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) * 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
CN1808446A (zh) * 2005-01-22 2006-07-26 鸿富锦精密工业(深圳)有限公司 高速电路中耦合传输线等效模型的撷取方法
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
CN101374829A (zh) * 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
PE20110224A1 (es) * 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
RU2009117701A (ru) * 2006-10-12 2010-11-20 Новартис АГ (CH) Производные пирролидина в качестве ингибиторов iap

Also Published As

Publication number Publication date
RU2009127800A (ru) 2011-01-27
US20120015974A1 (en) 2012-01-19
CA2671607A1 (en) 2008-07-03
KR20090094461A (ko) 2009-09-07
NZ577150A (en) 2012-04-27
AU2007337104A1 (en) 2008-07-03
CN101605786A (zh) 2009-12-16
EP2125809A1 (en) 2009-12-02
IL198927A0 (en) 2010-02-17
RU2466131C2 (ru) 2012-11-10
US20100130539A1 (en) 2010-05-27
JP2010513561A (ja) 2010-04-30
US8063218B2 (en) 2011-11-22
WO2008079735A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
BRPI0719481A2 (pt) " composto, método de indução de apoptose em uma célula, de sensibilização de uma célula, para inibir a ligação de uma proteína iap a uma proteína caspase, para tratar uma doença ou condição associada com a superexpressão de uma proteína iap e para tratar câncer"
RU2451025C2 (ru) Ингибиторы iap
KR100926203B1 (ko) Iap의 억제제
JP5368428B2 (ja) Iapのインヒビター
CA2588921C (en) Pyrrolidine inhibitors of iap
AU2009279924B2 (en) Inhibitors of IAP
US20110218211A1 (en) Azaindole inhibitors of iap
EP2240506B1 (en) Inhibitors of iap

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2284 DE 14/10/2014.